RT Journal Article
SR Electronic
T1 Mutational status of advanced lung adenocarcinoma in a Portuguese cohort
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4683
DO 10.1183/13993003.congress-2019.PA4683
VO 54
IS suppl 63
A1 Josué Pinto
A1 Catarina Sousa
A1 Natália Martins
A1 Sofia Teixeira
A1 Adriana Magalhães
A1 Gabriela Fernandes
A1 Venceslau Hespanhol
A1 Henrique Queiroga
A1 Hélder Novais E Bastos
YR 2019
UL http://erj.ersjournals.com/content/54/suppl_63/PA4683.abstract
AB Background: Lung cancer treatment paradigm has changed progressively based on tumor biomarkers. Next-generation sequencing (NGS) detects several mutations in oncogenic drivers, thus predicting the response to targeted therapies. This study aimed to understand the impact of mutational status in advanced lung adenocarcinoma (ADC) presentation and prognosis.Methods: A retrospective analysis of detected mutations and their clinical correlations was performed in patients with stage III-IV lung ADC, who performed a molecular study with NGS.Results: A total of 127 patients were studied (mean age 67.6±10.8 years, 63% male, 33.9% non-smokers, 82.6% stage IV). An oncogenic mutation was present in 63.1% of patients, most commonly KRAS mutation (27.6%), followed by EGFR mutation (14.2%) and ALK rearrangement (6.3%). KRAS mutation was mostly found in males (80%) and ex-smokers (48.6%), while EGFR mutation in females (77.8%) and non-smokers (61.1%), with p<0.001 and p=0.002, respectively. No differences were stated between groups with regards to age (p=0.966) and PD-L1 expression (p=0.424). Overall survival was shorter in KRAS-mutated patients, when compared to ALK and EGFR groups (7.1; 7.5; 10.4 months, p=0.231), while progression-free survival was shorter in ALK rearrangement, although submitted to targeted therapy in most cases (71.4%), when compared to KRAS and EGFR mutations (2.8; 3.6; 5.9 months, p=0.323).Conclusions: Molecular characterization plays a key role in stratifying patients that will benefit from targeted therapy, but also provides prognostic information that could support future clinical strategies for lung ADC patients.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4683.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).